| 9.63 -1.37 (-12.45%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, founded in 2000 and headquartered in Jerusalem, Israel. The company specializes in developing therapeutic drugs using its proprietary Accordion Pill platform technology, which was also developed in Israel. This innovative oral drug delivery system is engineered to boost the effectiveness and safety of both existing medications and those under development by employing a distinct mechanism that ensures gastric retention and a controlled release of the drug within the stomach. The company's most advanced product candidate is Accordion Pill Carbidopa/Levodopa, currently undergoing a Phase III clinical trial to manage Parkinson's disease symptoms in patients with advanced forms of the illness. Intec Pharma's pipeline also features Accordion Pill Zaleplon, which is in Phase III clinical trials as a treatment for inducing and maintaining sleep for individuals experiencing insomnia. Additionally, a product candidate designed to prevent and treat gastroduodenal and small bowel ulcers caused by Nonsteroidal Anti-Inflammatory Drugs has successfully completed its Phase I clinical trial. The company is further developing AP-CBD/THC, AP-THC, and AP-CBD, cannabinoid-based product candidates containing Cannabidiol and 9-Tetrahydrocannabinol, aimed at alleviating various pain conditions. Intec Pharma Ltd. has also entered into a research collaboration agreement with Merck to investigate the potential uses of its Accordion Pill platform in Merck's development initiatives. Originally known as Intec Pharmaceuticals (2000) Ltd., the company officially changed its name to Intec Pharma Ltd. in March 2004.
Thu, 17 Sep 2015
Intec Pharma May Have a Blockbuster - Barron's
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|